A new study on MOTS-c was published on October 14, 2026, in the journal Frontiers in Immunology. The publication is titled "Integrative transcriptomic and computational analysis associates Ms4a6c+ macrophages with fibrosis in radiation proctitis and computationally nominates MOTS-c as a candidate modulator."
The study reports an integrative transcriptomic and computational analysis examining fibrosis in radiation proctitis. According to the title, the work associates Ms4a6c+ macrophages with this fibrosis process. The analysis is described as computationally nominating MOTS-c as a candidate modulator in this context.
MOTS-c remains classified as an unapproved compound used only in research settings. No findings, outcomes, or efficacy data beyond the publication title and journal listing are described in the available event information. This brief reports the existence and bibliographic details of the publication only.
Readers interested in background on this compound can consult the compound overview for further context.